These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31733275)

  • 21. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.
    Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A
    Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.
    García-Cruz E; Huguet J; Piqueras M; Márquez MP; Peri L; Izquierdo L; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    World J Urol; 2012 Jun; 30(3):361-5. PubMed ID: 21833558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate Health Index density improves detection of clinically significant prostate cancer.
    Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
    BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
    Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
    Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Is it possible to increase the specificity for the performance of prostatic biopsy in patients with PSA between 4 and 10 ng/ml and free/total PSA ratio < 20%].
    Arrabal-Polo MA; Domínguez-Amillo A; Cano-García Mdel C; Arrabal-Martín M; López-Carmona Pintado F; Cózar Olmo JM
    Arch Esp Urol; 2015 Sep; 68(7):595-601. PubMed ID: 26331395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer.
    Morgentaler A
    J Sex Med; 2009 Feb; 6(2):574-7. PubMed ID: 19215619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
    Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
    Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
    Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI-RADS score v.2 in predicting malignancy in patients undergoing 5α-reductase inhibitor therapy.
    Forte V; Cavallo AU; Bertolo R; de Soccio V; Sperandio M; Bove P; Ciccariello M
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):150-155. PubMed ID: 32681155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dutasteride on the risk of prostate cancer.
    Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
    N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).
    Karamanolakis D; Lambou T; Bogdanos J; Milathianakis C; Sourla A; Lembessis P; Halapas A; Pissimissis N; Dessypris N; Petridou ET; Koutsilieris M
    Anticancer Res; 2006; 26(4B):3159-66. PubMed ID: 16886650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seminal citrate is superior to PSA for detecting clinically significant prostate cancer.
    Gregorio EP; Alexandrino AP; Schuquel ITA; da Costa WF; Rodrigues MAF
    Int Braz J Urol; 2019; 45(6):1113-1121. PubMed ID: 31808398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occult prostate cancer in men with low serum testosterone levels.
    Morgentaler A; Bruning CO; DeWolf WC
    JAMA; 1996 Dec; 276(23):1904-6. PubMed ID: 8968017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.